For example, when analyzing plasma cfDNA from pregnant women with a known breast cancer diagnosis using a genome-wide NIPT assay, we found that triple negative breast cancers were more frequently identified compared to hormone-positive or HER2-enriched tumors, potentially due to the presence of high-level gains and losses of cfDNA or high ctDNA loads in plasma of patients with the former tumors [29]. The gene discussed is ERBB2; the disease is breast cancer.